842 related articles for article (PubMed ID: 16648493)
1. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Lamers CH; Sleijfer S; Vulto AG; Kruit WH; Kliffen M; Debets R; Gratama JW; Stoter G; Oosterwijk E
J Clin Oncol; 2006 May; 24(13):e20-2. PubMed ID: 16648493
[No Abstract] [Full Text] [Related]
2. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Brouwers AH; Mulders PF; Oyen WJ
J Clin Oncol; 2008 Aug; 26(22):3808-9; author reply 3811-2. PubMed ID: 18669472
[No Abstract] [Full Text] [Related]
3. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Shuch B; Li Z; Belldegrun AS
BJU Int; 2008 Jun; 101 Suppl 4():25-30. PubMed ID: 18430119
[No Abstract] [Full Text] [Related]
4. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Jensen HK; Nordsmark M; Donskov F; Marcussen N; von der Maase H
BJU Int; 2008 Jun; 101 Suppl 4():41-4. PubMed ID: 18430123
[No Abstract] [Full Text] [Related]
5. Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.
Skapa P; Hyrsl L; Zavada J; Soukup J; Zamecnik J
J Clin Oncol; 2008 Aug; 26(22):3809-11; author reply 3811-2. PubMed ID: 18669473
[No Abstract] [Full Text] [Related]
6. Carbonic anhydrase IX: historical and future perspectives.
Oosterwijk E
BJU Int; 2008 Jun; 101 Suppl 4():2-7. PubMed ID: 18430115
[No Abstract] [Full Text] [Related]
7. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
Leppert JT; Lam JS; Pantuck AJ; Figlin RA; Belldegrun AS
BJU Int; 2005 Aug; 96(3):281-5. PubMed ID: 16042714
[TBL] [Abstract][Full Text] [Related]
9. Deal watch: Phase III antibody targeting tumour pH acquired in Prometheus deal.
Nat Rev Drug Discov; 2011 Jul; 10(7):482. PubMed ID: 21720396
[No Abstract] [Full Text] [Related]
10. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
11. [Comment to "Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression"].
Salinas AS
Actas Urol Esp; 2011 Feb; 35(2):87-8. PubMed ID: 21288602
[No Abstract] [Full Text] [Related]
12. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
Mulders P; Bleumer I; Debruyne F; Oosterwijk E
Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
[No Abstract] [Full Text] [Related]
13. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
Schroten C; Kraaij R; Veldhoven JL; Berrevoets CA; den Bakker MA; Ma Q; Sadelain M; Bangma CH; Willemsen RA; Debets R
J Immunol Methods; 2010 Jul; 359(1-2):11-20. PubMed ID: 20460126
[TBL] [Abstract][Full Text] [Related]
14. In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer.
Brouwers AH; Boerman OC; Oyen WJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8886; author reply 8886. PubMed ID: 16361579
[No Abstract] [Full Text] [Related]
15. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.
Pantuck AJ; Klatte T; Seligson D; Atkins M; Belldegrun A
J Clin Oncol; 2008 Jun; 26(18):3105-7; author reply 3107-9. PubMed ID: 18565906
[No Abstract] [Full Text] [Related]
17. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Dudek AZ; Yee RT; Manivel JC; Isaksson R; Yee HO
Anticancer Res; 2010 Mar; 30(3):987-92. PubMed ID: 20393025
[TBL] [Abstract][Full Text] [Related]
18. Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.
Lamers CH; van Elzakker P; van Steenbergen SC; Luider BA; Groot C; van Krimpen BA; Vulto A; Sleijfer S; Debets R; Gratama JW
Cytotherapy; 2013 May; 15(5):620-6. PubMed ID: 23388583
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia.
Pastorekova S; Ratcliffe PJ; Pastorek J
BJU Int; 2008 Jun; 101 Suppl 4():8-15. PubMed ID: 18430116
[No Abstract] [Full Text] [Related]
[Next] [New Search]
